ULS UL Solutions Inc.
Services-Testing Laboratories · NYSE · SEC CIK 1901440 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.1%
TTM net income YoY51.3%
TTM EPS YoY50.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin50.6%
Operating margin17.8%
Net margin16.1%
FCF margin15.1%
EBITDA margin23.9%
Returns
ROE35.4%
ROA15.6%
ROIC (approx.)28.5%
Asset turnover0.97x
Leverage & solvency
Liabilities / assets52.9%
Debt / equity0.45x
Current ratio2.09x
Interest coverage20.29x
Cash quality & payout
Operating cash flow / net income1.44x
Accruals ratio-6.8%
Payout ratio22.2%
Capex / revenue8.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $3.05B | $2.87B |
| Cost of revenue | $1.54B | $1.48B |
| Gross profit | $1.51B | $1.39B |
| SG&A expense | $953.00M | $931.00M |
| Operating income | $522.00M | $462.00M |
| Interest expense | $41.00M | $55.00M |
| Pretax income | $470.00M | $415.00M |
| Income tax | $125.00M | $70.00M |
| Net income | $325.00M | $326.00M |
| EBITDA | $710.00M | $634.00M |
| EPS (basic) | 1.62 | 1.63 |
| EPS (diluted) | 1.60 | 1.62 |
| Dividends declared per share | 0.52 | 0.50 |
| Weighted avg. shares (diluted) | 203.00M | 201.00M |
| Balance sheet | ||
| Cash & equivalents | $295.00M | $298.00M |
| Receivables | $422.00M | $380.00M |
| Current assets | $1.00B | $921.00M |
| PP&E, net | $699.00M | $631.00M |
| Goodwill | $656.00M | $633.00M |
| Intangibles | $48.00M | $58.00M |
| Total assets | $2.92B | $2.80B |
| Current liabilities | $760.00M | $740.00M |
| Short-term debt | $0 | $50.00M |
| Long-term debt | $491.00M | $692.00M |
| Total debt | $491.00M | $742.00M |
| Total liabilities | $1.63B | $1.87B |
| Shareholders' equity | $1.26B | $904.00M |
| Net debt | $196.00M | $444.00M |
| Shares outstanding | 201.03M | 200.17M |
| Cash flow statement | ||
| Operating cash flow | $600.00M | $524.00M |
| Capital expenditure | $197.00M | $237.00M |
| Free cash flow | $403.00M | $287.00M |
| Investing cash flow | -$204.00M | -$234.00M |
| Financing cash flow | -$396.00M | -$284.00M |
| Depreciation & amortization | $188.00M | $172.00M |
| Stock-based compensation | $47.00M | $23.00M |
| Dividends paid | $104.00M | $100.00M |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.